drugset

drugset / Trial / NCT00599313

Phase II Sunitinib Prog Met AIPC

NCT00599313 ↗

Phase 2 Completed 36 enrolled US Oncology Research Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

Timeline

Start: 2007-03
Primary completion: 2009-06
Completion: 2009-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	50 mg	Oral

Indications